Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

With shortages of its blockbuster obesity now declared resolved in the USA, Denmark’s Novo Nordisk (NOV: N) is moving to make ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its ...

Citi analyst Daniel Grosslight keeps a Sell rating on Hims & Hers (HIMS) with a $27 price target after Novo Nordisk (NVO) announced ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.

Novo Nordisk has announced the launch of NovoCare Pharmacy, a new initiative that will offer its weight-loss drug Wegovy ...